mRNA technology has the potential to address diseases globally that have not had effective vaccines nor treatments to date. Read this report to learn about the promise of mRNA to prevent and treat endemic diseases in resource-limited areas with the populations who would benefit the most.
FHI Clinical has long-standing relationships, a local team and broad expertise in sub-Saharan Africa. We're ready to help you confidently expand your research across the region, finding the best-fit countries and populations for your target indication and study type.
Our broad expertise, end-to-end services and ability to begin immediate collaboration with government, commercial and academic partners in more than 60 countries make us uniquely positioned to support the COVID-19 response. We address emerging pandemics, epidemics and outbreaks with expertise that supports health and research efforts globally. We are experienced in addressing the complex aspects of infectious diseases — from infection prevention and control to clinical research on diagnostics, vaccines and treatment.
FHI Clinical goes where our expertise is needed. Whether it requires working from a state-of-the-art facility or in a low-tech, rural setting, we provide services tailored to meet your study needs, from protocol design and site assessments to trial planning, implementation and management.
Participant recruitment and retention can be challenged by many factors such as a long follow-up period, lack of accessible sites and unclear expectations. Our team helps develop and implement agile solutions to overcome these difficulties, as described in this video for multiple studies including a global, multi-site oncology trial.
Investigating existing treatments for their efficacy to treat COVID-19 is important in some countries with limited access to new treatments, such as Ghana. In this project profile, Loice Magaria, Clinical Research Project Manager at FHI Clinical, discusses a study we’re supporting in Ghana to investigate COVID-19 treatments.
With infectious disease outbreaks, expanding immunity from previous infection and vaccination efforts can change where the outbreak is occurring. In this video, Loice Magaria, Clinical Research Project Manager at FHI Clinical discusses strategies implemented to address changing epidemiology in a study investigating COVID-19 treatments.
In this webinar, our panel of Africa-based researchers discuss the strong clinical research foundation, the community-centered approach and increasing regulatory harmonization in Africa. Watch to learn about the continent’s population diversity, expanding therapeutic area expertise and long-standing stakeholder engagement.
Discovered in the 1960s, coronaviruses (CoV) are a large group of RNA viruses in the family Coronaviridae that cause disease in humans and animal species. Human illness includes respiratory infections that range from the common cold to viral (direct) or bacterial (indirect) pneumonia and are especially serious in infants and at-risk adults. There are seven known coronavirus types/strains.
The Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL) network was established through a partnership between local Liberian and international partners, including the U.S. National Institutes of Health, World Health Organization and FHI Clinical, to provide sustainable research infrastructure to address diseases of public health importance.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA